Biocon Limited announced the commercial launch of its denosumab biosimilars, Bosaya and Aukelso, in the United States following U.S. FDA approval.
The products, granted interchangeable designation, address a market with estimated U.S. sales of $5 billion and serve over 10 million osteoporosis patients.
CEO Shreehas Tambe stated the launch expands the company's biosimilars portfolio and broadens access to affordable treatments for serious bone conditions.
The launch is a strategic expansion for Biocon, building on its leadership in oncology and immunology biosimilars.